Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06050928 · ClinicalTrials.gov registry record · Phase 1
Phase 1b, Open-Label Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of EP262 in Subjects With Chronic Inducible Urticaria
A Phase 1 study of Chronic Inducible Urticaria, sponsored by Escient Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 33
- Enrollment target
- 15
- Study locations
NCT06050928: Completed Phase 1 study of Chronic Inducible Urticaria, sponsored by Escient Pharmaceuticals.
NCT06050928 is a Phase 1 study of Chronic Inducible Urticaria that has completed, run by Escient Pharmaceuticals. The registered enrollment target is 33 participants, below the 226-participant average among 4 other Chronic Inducible Urticaria trials with a reported enrollment target (85% lower). The trial reports 15 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06050928, a Phase 1 study of Chronic Inducible Urticaria, has completed, sponsored by Escient Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 33 participants
- Enrollment target
- 15
- Study locations
Study Summary
This phase 1b trial will evaluate the effects of EP262 in subjects with Chronic Inducible Urticaria (CIndU), including symptomatic dermographism and cold urticaria.
Primary Outcome
Assessed by the incidence of treatment-emergent adverse events
Conditions Studied
Interventions
- DRUG Oral EP262
Study Locations (15)
Other
- Innovaderm Research Inc. - Montreal
- Gordon Sussman Clinical Research Inc. - North York
- Institut fur Allergieforschung Charite - Universitatsmedizin Berlin - Berlin
- Hospital del Mar - Barcelona
- Hospital Arnau de Vilanova - Valencia
Florida
- Advanced Clinical Research Institute - Tampa
Idaho
- Treasure Valley Medical Research - Boise
Kentucky
- Allergy & Asthma Specialists, P.S.C. - Owensboro
Maryland
- Johns Hopkins University - Baltimore
Ohio
- Bernstein Clinical Research Center, LLC - Cincinnati
Pennsylvania
- Allergy and Clinical Immunology Associates - Pittsburgh
South Carolina
- National Allergy and Asthma Research, LLC. - North Charleston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2023-08-30 |
| Est. Completion | 2024-10-22 |
| Phase | Phase 1 |
What the finished NCT06050928 record still lists
NCT06050928 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 33 participants, a relatively small participant target, below the 226-participant average among 4 other Chronic Inducible Urticaria trials with a reported enrollment target (85% lower).
The record links to 1 condition, with Chronic Inducible Urticaria appearing as the primary indexed condition, and to 1 intervention - of which Oral EP262 is the first listed.
NCT06050928 lists 15 locations in 11 states (Other, Florida, Idaho).
Frequently Asked Questions
What is clinical trial NCT06050928 about?
NCT06050928 is a clinical study titled "Phase 1b, Open-Label Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of EP262 in Subjects With Chronic Inducible Urticaria". This phase 1b trial will evaluate the effects of EP262 in subjects with Chronic Inducible Urticaria (CIndU), including symptomatic dermographism and cold urticaria.
What is the current status of trial NCT06050928?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 33 participants. The study started on 2023-08-30. Estimated completion is 2024-10-22.
What conditions does trial NCT06050928 study?
This clinical trial studies the following conditions: Chronic Inducible Urticaria.
What interventions are being tested in trial NCT06050928?
The interventions under investigation include: Oral EP262 (DRUG).
Who is sponsoring clinical trial NCT06050928?
This trial is sponsored by Escient Pharmaceuticals, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06050928 being conducted?
This trial has 15 study locations across Florida, Idaho, Kentucky, Maryland, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Inducible Urticaria
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Investigate Efficacy, Safety and Tolerability of Barzolvolimab Versus Placebo in Adults With Cold Induced Urticaria and Symptomatic Dermographism Inadequately Controlled by H1-antihistamines (EMBARQ - ColdU and SD)
RECRUITING · Phase 3
-
Study of BLU-808 in Chronic Inducible Urticaria (CIndU) and Chronic Spontaneous Urticaria (CSU)
RECRUITING · Phase 2
-
A Study to Investigate Efficacy, Safety, and Tolerability of Remibrutinib Compared With Placebo in Adults With CINDU Inadequately Controlled by H1-antihistamines
ACTIVE NOT RECRUITING · Phase 3
-
A Study of CDX-0159 in Patients With Chronic Inducible Urticaria
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02861898 · 33 participants · Phase 1
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
- NCT04871607 · 33 participants · Phase 2
Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma
- NCT05071937 · 33 participants · Phase 2
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
- NCT05168618 · 33 participants · Phase 2
Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI